Mark Sean O'donnell Net Worth

The estimated Net Worth of Mark Sean O'donnell is at least 1.18 百万$ dollars as of 12 March 2010. Mark donnell owns over 5,739 units of Atyr Pharma Inc stock worth over 17,051$ and over the last 16 years Mark sold LIFE stock worth over 1,167,327$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark donnell LIFE stock SEC Form 4 insiders trading

Mark has made over 4 trades of the Atyr Pharma Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Mark sold 5,739 units of LIFE stock worth 302,675$ on 12 March 2010.

The largest trade Mark's ever made was exercising 30,007 units of Atyr Pharma Inc stock on 12 March 2010 worth over 1,030,140$. On average, Mark trades about 8,431 units every 20 days since 2008. As of 12 March 2010 Mark still owns at least 8,974 units of Atyr Pharma Inc stock.

You can see the complete history of Mark donnell stock trades at the bottom of the page.

What's Mark donnell's mailing address?

Mark's mailing address filed with the SEC is 5791 VAN ALLEN WAY, , CARLSBAD, CA, 92008.

Insiders trading at Atyr Pharma Inc

Over the last 16 years, insiders at Atyr Pharma Inc have traded over 27,288,922$ worth of Atyr Pharma Inc stock and bought 966,653 units worth 5,761,237$ . The most active insiders traders include James C Blair、Gregory T Lucier、Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of 34,257$. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth 8,950$.

What does Atyr Pharma Inc do?

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation

Complete history of Mark donnell stock trades at Atyr Pharma Inc

Atyr Pharma Inc executives and stock owners

Atyr Pharma Inc executives and other stock owners filed with the SEC include:

• Dr. Sanjay S. Shukla,
  Pres, CEO & Director
• Sanjay Shukla,
  President, Chief Executive Officer, Director
• Jill M. Broadfoot,
  Chief Financial Officer
• Nancy E. Denyes Krueger,
  Gen. Counsel & Corp. Sec.
• Jill Broadfoot,
  Chief Financial Officer
• Nancy Denyes,
  General Counsel and Corporate Secretary
• Paul Schimmel,
  Independent Director
• John Clarke,
  Independent Chairman of the Board
• Svetlana Lucas,
  Independent Director
• Jeffrey Hatfield,
  Independent Director
• Jane Gross,
  Independent Director
• Timothy Coughlin,
  Independent Director
• Dr. David J. King,
  Scientific Consultant
• Dr. Melissa A. Ashlock,
  Sr. Advisor
• Dr. Ying J. Buechler,
  Exec. Director of Biologics Devel. & Manufacturing
• Peter Villiger,
  VP of Corp. Devel.
• Ashlee Dunston,
  Director of Investor Relations & Corp. Communications
• Xiang-Lei Yang Ph.D.,
  Founder
• Donald W Grimm,
  Director
• Arnold J Levine,
  Director
• Ronald Asbury Andrews,
  President, Medical Sciences
• George F Jr Adam,
  Director
• David C Uprichard,
  Director
• Gregory T Lucier,
  CEO
• Kelli Richard,
  Chief Accounting Officer
• Bradley G Lorimier,
  Director
• Peter Michael Leddy,
  SVP, Human Resources
• Balakrishnan S Iyer,
  Director
• Raymond V Dittamore,
  Director
• Per A Peterson,
  Director
• Craig J Mundie,
  Director
• Mark P Stevenson,
  President & COO
• Ora H. Pescovitz,
  Director
• Ronald A Matricaria,
  Director
• John A Cottingham,
  Chief Legal Officer
• David F Hoffmeister,
  Chief Financial Officer
• Claude Benchimol,
  SVP, Advanced Genomic Systems
• William H Longfield,
  Director
• Nicolas Barthelemy,
  President, Cell Systems
• John L Miller,
  President - Genetic Systems
• Mark Sean O'donnell,
  SVP, Global Operations & Serv.
• Peter Dansky,
  Pres, Molecular Biology Sys
• Bernd Brust,
  Pres, Commercial Operations
• Paul David Grossman,
  SVP, Corporate Strategy & Dev.
• W Ann Reynolds,
  Director
• Joseph C Beery,
  SVP, Chief Information Officer
• William S Shanahan,
  Director
• James C Blair,
  Director
• John Mendlein,
  Director
• Sara Zaknoen,